Human RCTPubMed ID: 18176997·2008

Semax as Adjunctive Therapy in Depressive Disorder: Cognitive Enhancement and Mood Improvement

Voĭtenko VF, Arushanian EB, Stepanov SS.

Human Psychopharmacology, 2008 · n = 64

Key finding

Semax + antidepressant reduced HAM-D scores 23% more than antidepressant alone; improved cognitive scores (Digit Span, Processing Speed) 31%.

Summary

RCT of semax as adjunct to standard antidepressant therapy in major depressive disorder measuring mood and cognitive symptoms.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaxL3

A synthetic peptide analog of ACTH(4-10) approved in Russia as a nootropic, studied for cognitive enhancement and neuroprotection.

More research on Semax

Semax Restores Behavioral Performance and Spatial Memory in Alzheimer Disease Model Mice

Neurobiology of Aging · 2011 · Animal Study

Semax Reduces Brain Inflammation and Microglial Activation After Stroke

Journal of Neuroimmunology · 2010 · Animal Study

Semax Effects on BDNF, NGF, and GDNF: Neurotrophic Factor Signaling in Recovery From Neuronal Injury

Journal of Molecular Neuroscience · 2010 · Animal Study

Semax Improves Optic Nerve Function and Visual Acuity in Patients with Optic Neuropathy

Journal of the Neurological Sciences · 2009 · Human RCT

Semax Effects on Immune Function: Enhanced T-Cell Proliferation and Altered Cytokine Profile

International Immunology · 2009 · Human Pilot